XENE Stock Earnings Estimates Decreased by HC Wainwright

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Stock analysts at HC Wainwright reduced their FY2026 earnings per share estimates for Xenon Pharmaceuticals in a report issued on Tuesday, November 10th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will earn ($4.53) per share for the year, down from their previous estimate of ($4.48). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($4.66) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q4 2026 earnings at ($1.14) EPS, Q2 2027 earnings at ($1.22) EPS, Q4 2027 earnings at ($1.25) EPS, FY2027 earnings at ($4.90) EPS, FY2028 earnings at ($4.07) EPS, FY2029 earnings at ($2.25) EPS and FY2030 earnings at ($0.44) EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Monday, November 9th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.02.

Several other equities research analysts have also weighed in on XENE. Guggenheim started coverage on Xenon Pharmaceuticals in a report on Tuesday, October 6th. They issued a “buy” rating and a $73.00 price objective for the company. Wedbush dropped their price objective on shares of Xenon Pharmaceuticals from $71.00 to $55.00 and set an “outperform” rating on the stock in a report on Friday, September 18th. Royal Bank Of Canada dropped their price objective on shares of Xenon Pharmaceuticals from $81.00 to $70.00 and set an “outperform” rating on the stock in a report on Friday, September 18th. Deutsche Bank lowered shares of Xenon Pharmaceuticals from a “buy” rating to a “hold” rating and cut their target price for the stock from $90.00 to $46.00 in a research report on Friday, September 18th. Finally, Robert W. Baird reduced their target price on shares of Xenon Pharmaceuticals from $97.00 to $90.00 and set an “outperform” rating for the company in a research note on Friday, September 18th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Xenon Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $71.31.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $42.10 on Thursday. Xenon Pharmaceuticals has a one year low of $33.38 and a one year high of $72.66. The business’s fifty day moving average price is $41.91 and its 200-day moving average price is $52.14. The stock has a market capitalization of $4.07 billion, a PE ratio of -8.96 and a beta of 0.11.

Institutional Trading of Xenon Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Covestor Ltd boosted its stake in Xenon Pharmaceuticals by 418.5% in the 3rd quarter. Covestor Ltd now owns 674 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 544 shares during the period. GAMMA Investing LLC increased its position in shares of Xenon Pharmaceuticals by 60.2% during the third quarter. GAMMA Investing LLC now owns 830 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 312 shares during the period. Global Retirement Partners LLC bought a new stake in shares of Xenon Pharmaceuticals during the second quarter valued at about $53,000. Quantbot Technologies LP purchased a new stake in shares of Xenon Pharmaceuticals in the second quarter worth about $57,000. Finally, Axiom Investment Management LLC purchased a new stake in shares of Xenon Pharmaceuticals in the first quarter worth about $58,000. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, insider Christopher Kenney sold 7,068 shares of the stock in a transaction on Friday, August 28th. The stock was sold at an average price of $60.25, for a total transaction of $425,847.00. Following the sale, the insider owned 2 shares in the company, valued at $120.50. This represents a 99.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Thomas Patrick Kelly purchased 15,000 shares of the business’s stock in a transaction dated Wednesday, September 30th. The stock was bought at an average cost of $37.32 per share, with a total value of $559,800.00. Following the completion of the acquisition, the chief financial officer directly owned 15,000 shares of the company’s stock, valued at approximately $559,800. This trade represents a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders own 2.91% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing medicines for neurological disorders. The company’s research emphasizes ion channels, proteins that help regulate the electrical activity of nerve cells. Its lead program is azetukalner, formerly known as XEN1101, an oral Kv7 potassium-channel opener being developed for seizure disorders, including focal epilepsy. Xenon is also advancing other drug candidates aimed at neurological conditions. Founded in 1996, Xenon is headquartered in Burnaby, British Columbia, and conducts drug development activities in North America.